^
Association details:
| Biomarker: | HLA-A*03 |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Published date:
01/01/2022
Excerpt:
HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in the MSK-IMPACT cohort (HR 1·48 per HLA-A*03 allele [95% CI 1·20–1·82], p=0·00022), the validation DFCI Profile cohort (HR 1·22 per HLA-A*03 allele, 1·05–1·42; p=0·0097), and in the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01–1·85; p=0·047).
DOI:
10.1016/S1470-2045(21)00582-9
